别名 4Ig-B7-H3、B7 homolog 3、B7-H3 + [6] |
简介 May participate in the regulation of T-cell-mediated immune response. May play a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. May be involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. Could also play a key role in providing the placenta and fetus with a suitable immunological environment throughout pregnancy. Both isoform 1 and isoform 2 appear to be redundant in their ability to modulate CD4 T-cell responses. Isoform 2 is shown to enhance the induction of cytotoxic T-cells and selectively stimulates interferon gamma production in the presence of T-cell receptor signaling. |
靶点 |
作用机制 CD276抑制剂 [+1] |
非在研适应症 |
最高研发阶段申请上市 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
作用机制 CD276调节剂 [+1] |
在研机构 |
原研机构 |
非在研适应症- |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 CD276抑制剂 |
在研机构 |
原研机构 |
非在研适应症 |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2025-02-28 |
申办/合作机构 |
开始日期2024-12-01 |
申办/合作机构 |
开始日期2024-12-01 |
申办/合作机构 |